AbbVie forecasts 2025 profit above estimates on newer immunology drugs
By Christy Santhosh and Puyaan Singh (Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira,
AbbVie Stock Soars on Key Drugs’ Sales Forecasts
AbbVie shares surged nearly 8% Friday morning, after the company substantially raised its sales forecasts for two key drugs. While reporting fourth-quarter revenue and earnings per share above Wall Street's estimates,
AbbVie Stock Soars as Biotech Tops Sales Estimates, Raises Outlook
AbbVie stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat inflammation.
AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%
AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered growth needed to offset declining sales of its blockbuster Humira.
AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs
AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthritis drug that now faces stiff competition.
ABBV Earnings: AbbVie Rallies Alongside Q4 Beats
AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news ...
BioSpace1h
AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure
After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...
Crain's Chicago Business3h
Abbvie's new drugs help brighten 2025 earnings outlook
The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...
AbbVie rises 7.8%
AbbVie (ABBV) is up 7.8%, or $13.78 to $189.43.Invest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover their success rate ...
Is AbbVie Stock a Buy?
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges
AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker ...
AbbVie: Q4 Earnings Snapshot
NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier.
AbbVie A Top Socially Responsible Dividend Stock With 3.9% Yield
The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...
AbbVie seeing ‘significant advancements’ across entire pipeline
EST AbbVie (ABBV) seeing ‘significant advancements’ across entire pipelineInvest with Confidence: Follow TipRanks' Top Wall Street ...